Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Shares Outstanding (Weighted Average) (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Shares Outstanding (Weighted Average) over the past 3 years, most recently at $641264.0 for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $641264.0 for Q4 2025, down 12.91% from a year ago — trailing twelve months through Dec 2025 was $641264.0 (down 12.91% YoY), and the annual figure for FY2025 was $641264.0, up 1304.31%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $641264.0 at Tonix Pharmaceuticals Holding, up from $26239.0 in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for TNXP hit a ceiling of $10.5 million in Q2 2024 and a floor of $3196.0 in Q2 2023.
  • Median Shares Outstanding (Weighted Average) over the past 3 years was $436393.5 (2024), compared with a mean of $2.5 million.
  • Peak annual rise in Shares Outstanding (Weighted Average) hit 329542.15% in 2024, while the deepest fall reached 99.73% in 2024.
  • Tonix Pharmaceuticals Holding's Shares Outstanding (Weighted Average) stood at $7925.0 in 2023, then surged by 9191.34% to $736339.0 in 2024, then fell by 12.91% to $641264.0 in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $641264.0 (Q4 2025), $26239.0 (Q3 2025), and $6.6 million (Q2 2025) per Business Quant data.